• linkedin
  • Increase Font
  • Sharebar

    Experts note the biggest impacts to derm in 2015




    IL-17 inhibitors for psoriasis

    Seth J. Orlow, M.D., Ph.D., professor of pediatric dermatology and chair of dermatology at NYU Langone Medical Center, New York, N.Y.: 2015 was a year of significant therapeutic developments in our specialty. Secukinumab, approved in 2015 for the treatment of psoriasis, represents the first of a series of inhibitors of IL-17 action that are in development, and sets new efficacy standards. And adalimumab, already so familiar to dermatologists as an effective treatment for psoriasis, was approved for the treatment of hidradenitis suppurative. An approved treatment that works well at least for some patients with HS was woefully needed, and it is great that the need for a treatment was recognized by the FDA. And finally, on the cosmetic side, two treatments are now available for submental fat, deoxycholic acid (approved as an injected drug) and cryolipolysis (cleared as a device).

    Lisette Hilton
    Lisette Hilton is a writer in Boca Raton, Fla., who heads up her company, Words Come Alive.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow